Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt

The Egyptian Journal of Bronchology

Table 3 Characteristics of COVID-19 infection prior to the vaccine in recruited cases (n = 369)

	COVID-19 vaccinated cases (n = 369)		P value*
	Group A (n = 299)	Group B (n = 70)	P value*
Duration before vaccination (days)	158 (8–670)	160 (19–466)	0.53
Diagnostic symptoms^a	52 (94.5%)	29 (96.7%)	0.55
Diagnostic CT chest^b	13 (23.6%)	4 (13.3%)	0.19
Severity			0.24
Mild	10 (19.2%)	4 (13.3%)
Moderate	23 (44.2%)	19 (63.3%)
Severe	19 (36.5%)	7 (23.3%)
Prior infection			< 0.001
Yes	55 (18.4%)	30 (42.9%)
No	244 (81.6%)	40 (57.1%)

Data expressed as frequency (percentage), median (range). Only significant values should be in boldface (P value was considered significant if < 0.05). COVID-19 coronavirus disease-19, CT computed tomography
^*Duration before vaccine was compared by Mann Whitney test while all other data were compared with Chi² test
^aInclude fever, myalgia, ageusia, anosmia, cough, diarrhea, rhinorrhea, sore throat, and dyspnea
^bCORAD 3 to CORAD 5